Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)

The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.

Lead sponsor: Pfizer•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETED

Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment

NCT01072539 · Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections, and more

COMPLETEDPhase 4

A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections

NCT00234949 · Mild to Moderate Uncomplicated Skin and Skin Structure Infections

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 8, 2011Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment621

Start dateApr 2007

Last updatedJul 8, 2011

Condition

Complicated Skin and Skin Structure Infections Complicated Intra-abdominal Infections

Locations shown

Pfizer Investigational Site

Manila

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 8, 2011Data synced to Clareo: July 12, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions